Novavax’s Latecomer COVID-19 Vaccine Impresses With 90% Efficacy Result
Role As Booster Could Be Key
Arriving two to three months later than planned, Novavax’s nanoparticle-based vaccine is still a welcome addition to the field, for both rich and poor countries.
